© istock
“These interim results are very encouraging,” Evan Anderson, a professor of infectious disease at Emory University Medical School and lead author on the paper, said in a statement.
“While there is still a lot of work to do before we have a vaccine that is proven to be safe and effective against COVID-19, this study provides critical information about the safety of the vaccine. Importantly, the vaccine resulted in a robust immune response.”
Moderna is one of a handful of companies working on a vaccine and is now in Phase 3 clinical trials in the United States.